BIOXYTRAN, INC (BIXT) Form 10-Q — May 15, 2026
Bioxytran reported a net loss of $2.07 million for the quarter ended March 31, 2026, with no revenue generated from operations. The company holds only $463,047 in cash against total liabilities of $5.01 million, resulting in a negative working capital of $4.55 million. Management disclosed substantial doubt about the company's ability to continue as a going concern, stating it needs to raise $3.7 million to fund operations through September 2026. The filing also reveals a material weakness in internal controls due to lack of segregation of duties and a default on a $805,000 convertible note since March 2025.
Key figures
- Revenue
- 0
- Total Debt
- 5010121
- Cash Position
- 463047
- Rd expense q1
- 225479
- Funding need usd
- 3700000
- Shares outstanding
- 113361886
- Derivative liability
- 476489
- Warrants outstanding
- 21042031
- Convertible note principal
- 805000
- Convertible note total due
- 1118685
Price after filing
Close on the filing date to close N calendar days later (from $0.03). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.